Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.

Also called NCT04714177

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04714177
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04714177. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2023-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
Acronym
ED-ICH
Condition
Intracerebral Hemorrhage
Intervention (Drug)
Edaravone Dexborneol
Intervention (Drug)
Placebo
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University (class: other)
Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04714177
Content hash
fa082262bf57efc23d79056342f1b16140a7c598d13b12ca97bcec6b06491798